Sign In  |  Register  |  About Santa Clara  |  Contact Us

Santa Clara, CA
September 01, 2020 1:39pm
7-Day Forecast | Traffic

  • Search Hotels in Santa Clara

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Insulet Corp (NQ: PODD )

193.30 +2.42 (+1.27%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jul 26, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,848,006
Open 196.58
Bid (Size) 185.00 (1)
Ask (Size) 199.75 (1)
Prev. Close 190.88
Today's Range 180.45 - 198.23
52wk Range 125.82 - 283.07
Shares Outstanding 68,873,869
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Why Is Omnipod Insulin Device Maker Insulet Stock Jumping Today?
Insulet Corporation shares are rising after the company reported stronger-than-expected second-quarter revenue, driven by high demand for Omnipod 5 and a raised full-year revenue outlook. 
Via Benzinga
Insulet Reports Preliminary Second Quarter 2024 Revenue Results
From Insulet Corporation
Via Business Wire

Performance

YTD
-7.56%
-7.56%
1 Month
-6.05%
-6.05%
3 Month
+17.74%
+17.74%
6 Month
-2.70%
-2.70%
1 Year
-31.18%
-31.18%

More News

Read More
A Closer Look at 7 Analyst Recommendations For Insulet
Via Benzinga
$1000 Invested In This Stock 15 Years Ago Would Be Worth $26,000 Today
Via Benzinga
Exploring the Growth Potential of NASDAQ:PODD as It Nears a Breakout.
Via Chartmill
Here's How Much $100 Invested In Insulet 15 Years Ago Would Be Worth Today
Via Benzinga
(PODD) - Analyzing Insulet's Short Interest
Via Benzinga
Why NASDAQ:PODD Is a Promising High-Growth Stock in the Midst of Consolidation.
Via Chartmill
Insulet to Announce Second Quarter 2024 Financial Results on August 8, 2024
From Insulet Corporation
Via Business Wire
Insulet’s SECURE-T2D Pivotal Trial Results Demonstrate Omnipod® 5 Improves Clinical Outcomes and Quality of Life in Type 2 Diabetes
From Insulet Corporation
Via Business Wire
$1000 Invested In Insulet 15 Years Ago Would Be Worth This Much Today
Via Benzinga
Insulet Announces Full Commercial Launch of Omnipod 5 with Expanded Sensor Integrations in the United Kingdom and the Netherlands
From Insulet Corporation
Via Business Wire
Looking Into Insulet's Recent Short Interest
Via Benzinga
Insulet Announces Omnipod 5 Launch in France and U.S. Innovation Updates
From Insulet Corporation
Via Business Wire
The 3 Best Diabetes Stocks to Buy in June 2024
Via InvestorPlace
7 Stocks That Could Safely 10X by 2030
Via InvestorPlace
Where Insulet Stands With Analysts
Via Benzinga
NASDAQ:PODD, a strong growth stock, setting up for a breakout.
Via Chartmill
Is NASDAQ:PODD suited for growth investing?
Via Chartmill
Insulet to Present at the Jefferies Global Healthcare Conference
From Insulet Corporation
Via Business Wire
MicroStrategy Was The Best Among These 10 Large-Cap Stocks Scoring Big Last Week (May 12-May 19, 2024): Are They In Your Portfolio?
Via Benzinga
Follow the Whales: 3 Genius Stocks the Smart Money Is Piling Into for Triple-Digit Gains
Via InvestorPlace
Will Insulet's Monopoly Crumble? Appellate Court Ruling Signals Shift in Automated Insulin Delivery Systems Market
Via Benzinga
Wall Street Trades Flat On Mixed Producer Inflation; Meme Stocks See Wild Ride, Bitcoin Drops: What's Driving Markets Tuesday?
Via Benzinga
Stocks Pause On Dismal Consumer Confidence; Yields, Dollar Rise As Inflation Expectations Kick Higher, Bitcoin Sinks: What's Driving Markets Friday?
Via Benzinga
Topics Economy
Exposures Interest Rates
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 SantaClara.com & California Media Partners, LLC. All rights reserved.